{"nct_id":"NCT05924880","title":"A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)","status":"COMPLETED","status_verified_date":"2025-03","start_date":"2023-07-21","start_date_type":"ACTUAL","primary_completion_date":"2025-02-07","primary_completion_date_type":"ACTUAL","completion_date":"2025-02-07","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["AZN"]}